An updated health economic model for type 2 diabetes shows that a holistic treatment approach — introducing GLP-1 receptor agonists and SGLT2 inhibitors early based on cardiovascular risk, not just blood sugar — leads to fewer clinical events and greater health benefits than glucose-focused management.
Beyond HbA1c: fewer eventsWhen the diabetes model selected treatments based on cardiovascular risk and comorbidities (not just blood sugar), it predicted fewer heart and kidney events — validating guidelines that recommend early GLP-1 RA and SGLT2i use.
What the researchers found
The updated Cardiff T2D model incorporated three key changes: (1) a holistic therapy selection/escalation module considering cardiovascular risk, comorbidities, and bodyweight — not just HbA1c; (2) updated risk factor progression equations based on UKPDS90 data; (3) novel risk equations capturing cardio-kidney-metabolic benefits of SGLT2 inhibitors and GLP-1 receptor agonists derived from clinical outcomes trial data.
Comparing holistic vs. conventional (glucose-centric) approaches for a newly diagnosed T2D population, the holistic model enabled earlier introduction of SGLT2i and GLP-1 RA — primarily driven by elevated cardiovascular risk. This resulted in fewer predicted clinical events (cardiovascular, renal) and additional health benefits compared to the glucose-focused approach.
Why it matters
Health economic models drive real-world treatment decisions — they inform guidelines, insurance coverage, and prescribing policies. If these models focus only on blood sugar, they underestimate the value of GLP-1 drugs and SGLT2 inhibitors, potentially delaying access to medications that save lives. By updating the model to capture the full cardio-kidney-metabolic benefits of these drugs, this study provides the economic evidence needed to support modern guidelines that recommend earlier use of these therapies in high-risk patients.
How the study worked
The researchers updated the existing Cardiff T2D health economic model by replacing the conventional glucose-centric therapy selection module with a holistic decision framework. Risk equations were updated using UKPDS90 data, and novel equations were derived from SGLT2i and GLP-1 RA cardiovascular outcomes trials. The significance of the updates was tested by modeling predicted outcomes and costs for a newly diagnosed T2D population under both conventional (HbA1c-only) and holistic (multi-factor) treatment approaches.
What this study cannot tell us
Health economic models are simplifications of reality and rely on assumptions about disease progression, treatment adherence, and costs that may not perfectly reflect individual patient experiences. The model outcomes are predictions, not observed clinical data. The novel risk equations for SGLT2i and GLP-1 RA benefits were derived from trial populations that may differ from real-world patients. The model does not account for all possible treatment combinations or patient preferences. Specific numerical outcomes (event rates, costs) are not detailed in the abstract.
How to read the evidence
This is a health economic modeling study, not a clinical trial. It synthesizes data from multiple clinical outcomes trials (UKPDS90, GLP-1 RA and SGLT2i cardiovascular trials) into a predictive framework. While it provides important policy-relevant evidence, model predictions carry inherent uncertainty and depend on input assumptions.
When this study was published
Published in 2025, this is a very current study reflecting the latest shift in diabetes management philosophy and health economic methodology.
The bigger picture
This study reflects a paradigm shift in diabetes care: from 'glucose-centric' management (the standard for 50+ years) to 'cardio-kidney-metabolic' management. GLP-1 receptor agonists and SGLT2 inhibitors have transformed diabetes treatment precisely because they provide organ protection independent of blood sugar control. Health economic models that still focus on HbA1c as the primary driver of treatment decisions are outdated and may produce misleading cost-effectiveness analyses, potentially restricting access to life-saving medications.
Questions still open
- How much do health economic models influence actual prescribing decisions and insurance coverage for GLP-1 drugs?
- Will updated models like this accelerate earlier GLP-1 RA and SGLT2i prescribing in countries where access is currently limited by cost-effectiveness thresholds?
- Can the model be further updated to incorporate newer dual and triple peptide agonists (tirzepatide, retatrutide) as they generate outcomes data?
Common questions
Why should diabetes treatment consider more than just blood sugar levels?
What does a health economic model tell us about diabetes treatment?
Read the original research
Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.
Diabetes, obesity & metabolism, 27(4), 1752-1761
Citation
McEwan, Phil; Foos, Volker; Roberts, Geraint; Jenkins, Robert H; Evans, Marc; Wheeler, David C; Chen, Jieling. (2025). Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.. Diabetes, obesity & metabolism, 27(4), 1752-1761. https://doi.org/10.1111/dom.16141